tiprankstipranks
Blurbs

NexImmune (NEXI) Receives a Buy from Barclays

Barclays analyst Peter Lawson maintained a Buy rating on NexImmune (NEXIResearch Report) today and set a price target of $2.00. The company’s shares closed yesterday at $1.26.

Lawson covers the Healthcare sector, focusing on stocks such as MacroGenics, Karyopharm Therapeutics, and CytomX Therapeutics. According to TipRanks, Lawson has an average return of 1.6% and a 42.32% success rate on recommended stocks.

NexImmune has an analyst consensus of Strong Buy, with a price target consensus of $3.50, which is a 177.78% upside from current levels. In a report released today, Raymond James also maintained a Buy rating on the stock with a $3.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on NexImmune’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $15.02 million. In comparison, last year the company had a GAAP net loss of $8.55 million

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NEXI in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ body’s T cells to generate immune response that mimics natural biology. Its creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.

Read More on NEXI:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles